Active ingredient Amprenavir interacts in the following cases:
There are no adequate data from the use of amprenavir in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.
This medicinal product should be used during pregnancy only after careful weighing of the potential benefits compared to the potential risk to the foetus.
Amprenavir-related material was found in rat milk, but it is not known whether amprenavir is excreted in human milk. A reproduction study in pregnant rats dosed from the time of uterine implantation through lactation showed reduced body weight gains in the offspring during the nursing period. The systemic exposure to the dams associated with this finding was similar to exposure in humans, following administration of the recommended dose. The subsequent development of the offspring, including fertility and reproductive performance, was not affected by the maternal administration of amprenavir.
No studies on the effects on ability to drive and use machines have been performed.